A Novel Ex Vivo Assay to Evaluate Functional Effectiveness of Plasmodium vivax Transmission-Blocking Vaccine Using Pvs25 Transgenic Plasmodium berghei

Plasmodium falciparum and Plasmodium vivax account for >90% global malaria burden. Transmission intervention strategies encompassing transmission-blocking vaccines (TBV) and drugs represent ideal public health tools to eliminate malaria at the population level. The availability of mature P. falci...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 2024-06, Vol.229 (6), p.1894
Main Authors: Cao, Yi, Hayashi, Clifford T H, Kumar, Nirbhay
Format: Article
Language:English
Subjects:
Animals
Antigens, Protozoan - genetics
Antigens, Protozoan - immunology
Antigens, Surface
Female
Humans
Malaria Vaccines - genetics
Malaria Vaccines - immunology
Malaria, Vivax - parasitology
Malaria, Vivax - prevention & control
Malaria, Vivax - transmission
Mice
Plasmodium berghei - genetics
Plasmodium berghei - immunology
Plasmodium vivax - genetics
Plasmodium vivax - immunology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Plasmodium falciparum and Plasmodium vivax account for >90% global malaria burden. Transmission intervention strategies encompassing transmission-blocking vaccines (TBV) and drugs represent ideal public health tools to eliminate malaria at the population level. The availability of mature P. falciparum gametocytes through in vitro culture has facilitated development of a standard membrane feeding assay to assess efficacy of transmission interventions against P. falciparum. The lack of in vitro culture for P. vivax has significantly hampered similar progress on P. vivax and limited studies have been possible using blood from infected patients in endemic areas. The ethical and logistical limitations of on-time access to blood from patients have impeded the development of P. vivax TBVs. Transgenic murine malaria parasites (Plasmodium berghei) expressing TBV candidates offer a promising alternative for evaluation of P. vivax TBVs through in vivo studies in mice, and ex vivo membrane feeding assay (MFA). We describe the development of transmission-competent transgenic TgPbvs25 parasites and optimization of parameters to establish an ex vivo MFA to evaluate P. vivax TBV based on Pvs25 antigen. The MFA is expected to expedite Pvs25-based TBV development without dependence on blood from P. vivax-infected patients in endemic areas for evaluation.
ISSN:0022-1899
1537-6613
1537-6613
DOI:10.1093/infdis/jiae102